This review highlights how diabetes-associated metabolic imbalances alter lipoprotein structure and function, accelerating atherosclerotic plaque formation and cardiovascular risk in T2DM.
This review highlights the pathophysiological mechanisms by which altered lipoprotein metabolism in type 2 diabetes accelerates atherogenesis, emphasizing the need for improved cardiovascular risk assessment strategies.
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease, characterized by raised blood glucose levels and impaired lipid metabolism resulting from insulin resistance and relative insulin deficiency. In diabetes, the peculiar plasma lipoprotein phenotype, consisting in higher levels of apolipoprotein B-containing lipoproteins, hypertriglyceridemia, low levels of HDL cholesterol, elevated number of small, dense LDL, and increased non-HDL cholesterol, results from an increased synthesis and impaired clearance of triglyceride rich lipoproteins. This condition accelerates the development of the atherosclerotic cardiovascular disease (ASCVD), the most common cause of death in T2DM patients. Here, we review the alteration of structure, functions, and distribution of circulating lipoproteins and the pathophysiological mechanisms that induce these modifications in T2DM. The review analyzes the influence of diabetes-associated metabolic imbalances throughout the entire process of the atherosclerotic plaque formation, from lipoprotein synthesis to potential plaque destabilization. Addressing the different pathophysiological mechanisms, we suggest improved approaches for assessing the risk of adverse cardiovascular events and clinical strategies to reduce cardiovascular risk in T2DM and cardiometabolic diseases.
Luciani et al. (Wed,) conducted a review in Type 2 diabetes mellitus (T2DM) and atherosclerotic cardiovascular disease. Diabetes-associated metabolic imbalances and lipoprotein alterations was evaluated. This review highlights how diabetes-associated metabolic imbalances alter lipoprotein structure and function, accelerating atherosclerotic plaque formation and cardiovascular risk in T2DM.